July 11, 2022 02:27 PM EDTUpdated July 12, 08:44 AM

Amgen's blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says

Paul Schloesser

Associate Editor

It’s been only about one year since Amgen’s KRAS-targeted NSCLC drug Lumakras has been marketed in the US, and already analysts are warning of waning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen's blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Am­gen's block­buster hope­ful Lumakras sees slow­er than ex­pect­ed sales in lat­est da­ta, an­a­lyst says

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Amgen's blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?